Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-15T02:33:07.261Z Has data issue: false hasContentIssue false
  • English
  • Français

Tyramine and New Monoamine Oxidase Inhibitor Drugs

Published online by Cambridge University Press:  06 August 2018

G.M. Simpson  and
J. de Leon
G.M. Simpson
Affiliation:
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia, USA
J. de Leon
Affiliation:
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

The hypertensive crisis induced by the ingestion of cheese in subjects undergoing treatment with monoamine oxidase inhibitors (MAOIs) led to their virtual disappearance in many parts of the world. Three strategies to try and diminish the risk of this reaction have been developed: the combination of current (irreversible and non-selective) MAOIs with tricyclic antidepressants, the use of new selective MAOIs, and the use of new reversible MAOIs. The relative effectiveness of these different approaches can be assessed by the tyramine pressor test. The introduction of reversible and selective monoamine oxidase-A (MAO-A) inhibitors looks especially promising clinically.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 32 - 37
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amrein, R., Allen, S.R., Vranesik, D., et al (1988) Antidepressant drug therapy: associated risks. Journal of Neural Transmission, (suppl 26), 73–86.Google Scholar
Asatoor, A.M., Levi, A.J. & Milne, M.D. (1963) Tranylcypromine and cheese. Lancet, ii, 733–734.Google Scholar
Beaumont, G. (1973) Drug interactions with clomipramine (anafranil). Journal of International Medical Research, 1, 480–484.CrossRefGoogle Scholar
Bieck, P.R. & Antonin, K.H. (1982) Monoamine oxidase inhibitor by tranylcypromine: assessment in human volunteers. European Journal of Clinical Pharmacology, 22, 301–308.CrossRefGoogle ScholarPubMed
Bieck, P.R., Creimer, G., Gleiter, G., et al (1983) Effect of the reversible MAO inhibitor CGP 11305 A on blood pressure after oral tyramine. Presented at 2nd World Conference on Clinical Pharmacology and Therapeutics, Washington, DC.Google Scholar
Birkmayer, W. & Riederer, P. (1983) Parkinson's Disease. Vienna: Springer Verlag.Google ScholarPubMed
Blackwell, B. (1963) Hypertensive crisis due to monoamine oxidase inhibitors. Lancet, ii, 849–851.CrossRefGoogle Scholar
Blackwell, B. (1970) The process of discovery. In Discoveries in Biological Psychiatry (ed. Ayd, F.J. & Blackwell, B.). Philadelphia: Lippincott.Google Scholar
Blackwell, B., Marley, E., Price, J., et al (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry, 113, 349–365.CrossRefGoogle ScholarPubMed
Burn, J.H. & Rand, M.J. (1958) The action of sympathomimetic amines in animals treated with reserpine. Journal of Physiology (London), 144, 314–316.CrossRefGoogle ScholarPubMed
Casacchia, M., Carolei, A., Barba, C., et al (1984) A placebo-controlled study of the anti-depressant activity of moclobemide; a new MAO-A inhibitor. Pharmacopsychiatry, 17, 122–125.Google Scholar
Coppen, A. & Ghose, K. (1978) Peripheral alpha-adrenoreceptor and central dopamine receptor activity in depressive patients. Psychopharmacology, 59, 171–177.Google Scholar
Da Prada, M., Zurcher, G., Wuthrich, I., et al (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission, (suppl 26), 31–56.Google Scholar
Elsworth, J.D., Glover, V., Reynolds, G.P., et al (1978) Deprenyl administration: a selective monoamine oxidase B inhibitor without the cheese effect? Psychopharmacology, 57, 33–38.Google Scholar
Faraj, B.A., Carrano, R.A., Ali, F.M., et al (1981) Studies of the effect of antidepressants on kinetics and metabolism of tyramine. Journal of Pharmacology and Experimental Therapeutics, 218, 750–757.Google Scholar
Fowler, J.S., Macgregor, R.R., Wolf, A.P., et al (1987) Mapping human brain monoamine oxidase A and B with 11C-labelled suicide inactivators and PET. Science, 235, 481–485.Google Scholar
Ghose, K. (1984) Tyramine pressor test: implications and limitations. Methods and Findings in Experimental and Clinical Pharmacology, 6, 455–464.Google ScholarPubMed
Gieschke, R., Schmid, K.W. & Ziegler, W.H. (1988) Interactions of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission, (suppl 26), 97–104.Google Scholar
Graham, P.M. & Ilett, K.F. (1988) Danger of MAOI therapy after fluoxetine withdrawal. Lancet, ii, 1255–1256.Google Scholar
Kapfhammer, H.P., Dieterle, D., Golling, H., et al (1986) Cimoxatone and moclobemide, two new MAO-inhibitors in the treatment of major depressive disorder. Pharmacopsychiatry, 19, 247–248.Google Scholar
Keller, H.H., Kettler, R., Keller, G., et al (1987) Short-acting novel MAO-inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedeberg's Archives of Pharmacology, 335, 12–20.Google Scholar
Konradi, C., Riederer, P., Jellinger, K., et al (1987) Cellular action of MAO inhibitors. Journal of Neural Transmission, (suppl 25), 15–25.Google Scholar
Korn, A., Eichler, H.G., Fischbach, R., et al (1986) Moclobemide; a new reversible MAO inhibitor — interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology, 88, 1153–1157.CrossRefGoogle ScholarPubMed
Korn, A., Raffesberg, W., et al (1988a) Tyramine pressor effect in man: studies with moclobemide, a novel reversible monoamine oxidase inhibitor. Journal of Neural Transmission, (suppl 26), 57–71.Google Scholar
Korn, A., Raffesberg, W., et al (1988b) Effect of moclobemide, a new reversible monoamine oxidase inhibitor on absorptions and pressor effect of tyramine. Journal of Cardiovascular Pharmacology, 11, 17–23.Google Scholar
Lader, M.H., Sakalis, G. & Tansella, M. (1970) Interactions between sympathetic amines and a new monoamine oxidase inhibitor. Psychopharmacology, 18, 118–123.CrossRefGoogle Scholar
Lam, R.W. (1987) L-Deprenyl, a selective MAO-B inhibitor. Jefferson Journal of Psychiatry, 5, 26–32.Google Scholar
Larsen, J.K., Holm, P. & Mikkelson, P.L. (1984) Moclobemide and clomipramine in the treatment of depression. Acta Psychiatrica Scandinavica, 70, 254.Google Scholar
Lipper, S., Murphy, D.L., Slater, S., et al (1979) Comparative behavioural effects of clorgyline and parayline in man: a preliminary evaluation. Psychopharmacology, 62, 123–128.Google Scholar
Mann, J.J., Frances, A., Kaplan, R.D., et al (1982) The relative efficacy of l-deprenyl a selective monoamine oxidase type B inhibitor in endogenous and nonendogenous depression. Journal of Clinical Psychopharmacology, 2, 54–57.Google Scholar
Mann, J.J., Aaron, S.F., Frances, A.J., et al (1984) Studies of selective and reversible monoamine oxidase inhibitors. Journal of Clinical Psychiatry, 45, 62–66.Google Scholar
Mann, J.J., Aaron, S.F., Wilner, P.J., et al (1989) A controlled study of the anti-depressant efficacy and side effects of (—) deprenyl: a selective monoamine oxidase inhibitor. Archives of General Psychiatry, 46, 45–50.Google Scholar
Mendis, N., Pare, C.M.B., Sandler, M., et al (1981) Is the failure of (—) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology, 73, 87–90.Google Scholar
Mendlewicz, J. & Youdim, M.B.H. (1983) l-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression: a double-blind evaluation. British Journal of Psychiatry, 142, 508–511.CrossRefGoogle ScholarPubMed
Mulgirigama, L.D., Pare, C.M.B., Turner, P., et al (1977) Tyramine pressor responses and plasma levels during tricyclic antidepressant therapy. Postgraduate Medical Journal, 53 (suppl. 4), 30–34.Google Scholar
Muller, T., Gieschke, R. & Ziegler, W.H. (1988) Blood pressure response to tyramine enriched meal before and during MAO-inhibition in man: influences of dosage regimen. Journal of Neural Transmission, (suppl 26), 105–114.Google Scholar
Murphy, D.L., Garrick, N.A., Aulakh, C.S.R., et al (1984) New contributions to understanding the effects of monoamine oxidase inhibition antidepressants. Journal of Clinical Psychiatry, 45, 37–43.Google ScholarPubMed
Murphy, D.L., Aulakh, C.S., Garrick, N.A., et al (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In Psychopharmacology: The Third Generation of Progress. in Psychopharmacology: The Third Generation of Progress (ed. Meltzer, H.Y.). New York: Raven Press.Google Scholar
Norman, T.R., Ames, D., Burrows, G.D., et al (1985) A controlled study of a specific MAO-A reversible inhibitor (Ro 11–1163) and amitriptyline in depressive illness. Journal of Affective Disorders, 8, 29–35.CrossRefGoogle ScholarPubMed
Nutt, D. & Glue, P. (1989) Monoamine oxidase inhibitors: rehabilitation from recent research? British Journal of Psychiatry, 154, 287–291.Google Scholar
Pace, D.G., Stoots, B.R., Rozi, K.L.M., et al (1988) Evaluation of methods of administering tyramine to raise systolic blood pressure. Clinical Pharmacology and Experimental Therapeutics, 44, 137–144.Google Scholar
Pare, C.M.B., Hallstrom, C., Kline, N., et al (1982) Will amitriptyline prevent the ‘cheese’ reaction of monoamine-oxidase inhibitors? Lancet, ii, 183–186.CrossRefGoogle Scholar
Pare, C.M.B., Mousawi, M.A., Sandler, M., et al (1985) Attempts to attenuate the ‘cheese effect': combined drug therapy in depressive illness. Journal of Affective Disorders, 9, 137–141.CrossRefGoogle ScholarPubMed
Pickar, D., Cohen, R.M., Jimerson, D.C., et al (1981) Tyramine infusions and selective monoamine oxidase inhibitor treatment. I Changes in pressor sensitivity. Psychopharmacology, 74, 4–7.CrossRefGoogle Scholar
Quitkin, F.M., Liebowitz, M.R., Stewart, J.W., et al (1984) l-Deprenyl in atypical depressives. Archives of General Psychiatry, 41, 777–781.Google Scholar
Rafaelsen, O.J. (1988) Cheese effects and new reversible MAO-A inhibitors: summary. Journal of Neural Transmission, (suppl 26), 123–124.Google Scholar
Razani, J., White, K.L., White, J., et al (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment: a controlled trial. Archives of General Psychiatry, 40, 657–661.CrossRefGoogle ScholarPubMed
Simpson, G. & White, K. (1984) Tyramine studies and the safety of MAOI drugs. Journal of Clinical Psychiatry, 45, 59–61.Google Scholar
Simpson, G., White, K., Pi, E., et al (1983) Monoamine oxidase inhibition and tyramine sensitivity in l-deprenyl-treated subjects. Psychopharmacology Bulletin, 19, 340–342.Google Scholar
Sunderland, T., Mueller, E.A., Cohen, R.M., et al (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology, 86, 432–437.Google Scholar
Tariot, P.N., Cohen, R.N., Sunderland, T., et al (1987) L-Deprenyl in Alzheimer's disease: preliminary evidence for behavioural change with monoamine oxidase B inhibitor. Archives of General Psychiatry, 44, 427–433.CrossRefGoogle Scholar
Tiller, J.W.G., Maguire, K.P. & Davies, B.M. (1987) Tyramine pressor response with moclobemide, a reversible monoamine oxidase inhibitor. Psychiatry Research, 22, 213–220.CrossRefGoogle ScholarPubMed
Vaccari, A. (1986) High affinity binding of (3H)-tyramine in the central nervous system. British Journal of Pharmacology, 89, 15–25.Google Scholar
Wheatley, D. (1970) Comparative trial of a new monoamine oxidase inhibitor in depression. British Journal of Psychiatry, 117, 573–574.Google Scholar
White, K. & Simpson, G. (1981) Combined MAOI-tricyclic antidepressant treatment: a reevaluation. Journal of Clinical Psychopharmacology, 1, 264–282.CrossRefGoogle ScholarPubMed
White, K. & Simpson, G. (1984) The combined use of MAOI's and tricyclics. Journal of Clinical Psychiatry, 45, 67–69.Google Scholar
White, K. & Simpson, G. (1985) Should the use of MAO inhibitors be abandoned? Integrative Psychiatry, 3, 34–38.Google Scholar
Youdim, M.B.H. & Finberg, J.P.M. (1985) Monoamine oxidase inhibitor antidepressant. In Psychopharmacology 2, Part 1: Preclinical Psychopharmacology (ed. Grahame-Smith, D.G.). Amsterdam: Elsevier.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.